View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 21, 2020

Vaxart progresses oral Covid-19 vaccine into clinical trials

By Allie Nawrat

San Francisco-based Vaxart has announced positive pre-clinical results for its oral Covid-19 vaccine candidates.

Oral vaccines are administered by tablet, rather than through injection; Vaxart deems this method to be more convenient and easier to distribute and administer on a large scale. Oral vaccination has been highly effective in ongoing polio eradication efforts.

Vaxart’s vaccine candidates were developed using the company’s proprietary VAAST vaccines platform, and the immune responses in all the vaccinated groups were statistically significant, compared to controls.

Vaxart chief executive Wouter Latour said: “These results are extremely encouraging, and we should be in a position to select a lead development candidate for cGMP manufacturing and clinical testing in the coming weeks.

“Our oral vaccines have been shown to protect against respiratory infection based on mucosal immunity, the first line of defence for such infections.

“This could be important for an effective vaccine that protects the global population from Covid-19.”

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU